Kepler Capital Sticks to Their Buy Rating for MedinCell SA (MEDCL)
Kepler Capital analyst Nicolas Pauillac maintained a Buy rating on MedinCell SA (MEDCL – Research Report) on February 26 and set a price ...
3 European Growth Companies With Up To 19% Insider Ownership
As European markets navigate a landscape marked by cautious optimism amid U.S. trade policy developments and geopolitical efforts, investors are increasingly focused on companies with strong growth ...
Pharmabiz2d
Teva Pharma, Medincell announce US FDA acceptance of sNDA for Uzedy to treat people living with schizophrenia
Parsippany, New Jersey Thursday, February 27, 2025, 13:00 Hrs [IST] ...
Pharm Exec2d
FDA Accepts Supplemental New Drug Application for Teva, Medincell’s Uzedy for Bipolar I Disorder
The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...
Medincell to Present at the TD Cowen 45th Annual Healthcare Conference, March 3-5, 2025, Boston, MA
Christophe Douat, CEO, and Richard Malamut, CMO, will present Medincell’s corporate overview at the TD Cowen 45 th Annual Healthcare Conference on Monday, March 3, 2025, at 9:50am ET. Live webcast and ...
The Pharma Letter3d
FDA accepts Teva and Medincell’s Uzedy sNDA
Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...
FDA accepts Teva's application for Uzedy for bipolar I disorder
The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...
FDA accepts Teva & Medincell’s UZEDY sNDA for extended-release to treat BP-I
Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...
Investing4d
FDA accepts Teva, Medincell’s supplemental application for UZEDY as bipolar I disorder treatment
UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...